Psoriasis and Vascular Disease: An Unsolved Mystery

American Journal of Medicine

Volumn 121, Issue 5, 2008, Pages 360-365

  Shelling, Michael L ^a   Federman, Daniel G ^b   Prodanovich, Srdjan ^a   Kirsner, Robert S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Atherosclerosis; Cardiovascular risk factors; Coronary artery disease; Myocardial infarction; Psoriasis; Systemic inflammation

Indexed keywords

ARTHROPATHY; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISTRESS SYNDROME; ENVIRONMENTAL FACTOR; HEART INFARCTION; HUMAN; INFLAMMATION; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; REVIEW; SKIN MANIFESTATION; THROMBOSIS; VASCULAR DISEASE;

HUMANS; PSORIASIS; VASCULAR DISEASES;

EID: 43049094410     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.01.025     Document Type: Review

References (55)

1. National Psoriasis Foundation. Psoriasis statistics. www.psoriasis.org/about/stats Accessed April 6, 2007
2. Schon M.P., and Boehncke W.B. Psoriasis. N Engl J Med 352 (2005) 1899-1912
3. Farber E.M., and Nall M.L. The natural history of psoriasis in 5,600 patients. Dermatologica 148 (1974) 1-18
4. Naldi L., Parazzini F., Brevi A., et al. Family history, smoking habits, alcohol consumption and risk of psoriasis. Br J Dermatol 127 (1992) 212-217
5. Farber E.M., Nall M.L., and Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol 109 2 (1974) 207-211
6. Lebwohl M. Psoriasis. Lancet 361 (2003) 1197-1204
7. Krueger G., and Ellis C.N. Psoriasis-recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 53 (2005) S94-S100
8. Lee M.G., and Cooper A.J. Immunopathogenesis of psoriasis. Australas J Dermatol 47 (2006) 151-159
9. Krueger J.G., and Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 64 Suppl 2 (2005) ii30-ii36
10. Zheng Y., Danilenko D.M., Valdez P., et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445 (2007) 648-651
11. Nickoloff B.J. Cracking the cytokine code in psoriasis. Nat Med 13 (2007) 242-244
12. Krueger G.G., Langley R.G., Leonardi C., et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356 (2007) 580-592
13. Henseler T., and Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 32 (1995) 982-986
14. Shapiro J., Cohen A.D., David M., et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 56 (2007) 629-634
15. Mallbris L., Granath F., Hamsten A., and Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 54 (2006) 614-621
16. Rocha-Pereira P., Santos-Silva A., Rebelo I., et al. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 303 (2001) 33-39
17. Sommer D.M., Jenisch S., Suchan M., et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 298 (2006) 321-328
18. Neimann A.L., Shin D.B., Wang X., et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55 (2006) 829-835
19. Kimhi O., Caspi D., Bornstein N.M., et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 36 (2007) 203-209
20. Kural B.V., Orem A., Cimsit G., et al. Plasma homocysteine and its relationship with atherothrombotic markers in psoriatic patients. Clin Chim Acta 332 (2003) 23-30
21. Stein J.H., and McBride P.E. Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment. Arch Intern Med 158 (1998) 1301-1306
22. Van Guldener C., and Stehouwer C.D. Homocysteine and large arteries. Adv Cardiol 44 (2007) 278-301
23. Bhushan M., McLaughlin B., Weiss J.B., and Griffiths C.E.M. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 141 (1999) 1054-1060
24. Simonetti O., Lucarini G., Goteri G., et al. VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: results of an immunohistochemical study. Int J Immunopathol Pharmacol 19 (2006) 751-760
25. Herron M.D., Hinckley M., Hoffman M.S., et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 141 (2005) 1527-1534
26. Naldi L., Chatenoud L., Linder D., et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 125 (2005) 61-67
27. Fortes C., Mastroeni S., Leffondre K., et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 141 (2005) 1580-1584
28. Setty A.R., Curhan G., and Choi H.K. Smoking and the risk of psoriasis in women: Nurses' Health Study II. Am J Med 120 (2007) 953-959
29. Esposito M., Saraceno R., Giunta A., et al. An Italian study of psoriasis and depression. Dermatology 212 (2006) 123-127
30. Russo P.A., Ilchef R., and Cooper A.J. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol 45 (2004) 155-159
31. Kimball A.B., Jacobson C., Weiss S., et al. The psychosocial burden of psoriasis. Am J Clin Dermatol 6 (2005) 383-392
32. Schmitt J.M., and Ford D.E. Role of depression in quality of life for patients with psoriasis. Dermatology 215 (2007) 17-27
33. Parashar S., Rumsfeld J.S., Spertus J.A., et al. Time course of depression and outcome of myocardial infarction. Arch Intern Med 166 (2006) 2035-2043
34. Frasure-Smith N., Lesperance F., and Talajic M. Depression following myocardial infarction. Impact on 6-month survival. JAMA 270 (1993) 1819-1825
35. Frasure-Smith N., Lesperance F., and Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 91 (1995) 999-1005
36. McDonald C.J., and Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 99 (1978) 469-475
37. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 172 (1986) 298-304
38. Pearce D.J., Morrison A.E., Higgins K.B., et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat 16 (2005) 319-323
39. Ludwig R.J., Herzog C., Rostock A., et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 156 (2007) 271-276
40. Gelfand J.M., Neimann A.L., Shin D.B., et al. Risk of myocardial infarction in patients with psoriasis. JAMA 296 (2006) 1735-1741
41. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
42. Willerson J.T., and Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 109 (2004) II2-II10
43. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
44. Wolfe F., Freundlich B., and Straus W.L. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 30 (2003) 36-40
45. Rhew E.Y., and Ramsey-Goldman R. Premature atherosclerotic disease in systemic lupus erythematosus-role of inflammatory mechanisms. Autoimmun Rev 5 (2006) 101-105
46. Christophers E. Comorbidities in psoriasis. J Eur Acad Dermatol Venereol 20 (2006) 52-55
47. Wolfe F., Mitchell D.M., Sibley J.T., et al. The mortality of rheumatoid arthritis. Arthritis Rheum 37 (1994) 481-494
48. Han C., Robinson D.W., Hackett M.V., et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33 (2006) 2167-2172
49. Maradit-Kremers H., Nicola P.J., Crowson C.S., et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52 (2005) 722-732
50. Pham T., Gossec L., Constantin A., et al. Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 73 (2006) 379-387
51. Prodanovich S., Ma F., Taylor J.R., et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 52 (2005) 262-267
52. Jacobsson L.T., Turesson C., Gulfe A., et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32 (2005) 1213-1218
53. Markham T., Mullan R., Golden-Mason L., et al. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol 54 (2006) 1003-1012
54. Mastroianni A., Minutilli E., Mussi A., et al. Cytokine profiles during infliximab monotherapy in psoriatic arthritis. Br J Dermatol 153 (2005) 531-536
55. Lebwohl M. A clinician's paradigm for the treatment of psoriasis. J Am Acad Dermatol 53 (2005) S59-S69